Mason Lankes

Mason Lankes
TG Therapeutics Surpasses Revenue Guidance and Delivers Strong Q4 Results Amid Exciting Business Milestones

TGTX

TG Therapeutics Surpasses Revenue Guidance and Delivers Strong Q4 Results Amid Exciting Business Milestones

TG Therapeutics, a biotechnology company focused on developing and commercializing innovative therapies for diverse patient populations, has reported outstanding fourth-quarter (Q4) and full-year 2024 financial results, exceeding its targeted revenue guidance. The company's full-year 2024 U.S. revenues of $310 million significantly outperformed its initial projections, demonstrating the

By Mason Lankes